Enrollment continues in dry eye trial amid coronavirus outbreak

RegeneRx Biopharmaceuticals, in association with its Korean partner GtreeBNT, announced a status update in response to the COVID-19 pandemic on a phase 3 clinical trial of RGN-295 for the treatment of dry eye disease, according to a press release.

The double-masked, placebo-controlled, randomized phase 3 ARISE-3 clinical trial is expected to complete enrollment of 700 patients in the United States as planned and is nearing the interim enrollment target of 500 patients. In addition, sequential initiation will continue, with an emphasis on areas where the coronavirus is less prevalent, the release said.

Steps are being taken to manage the distance between patients at enrollment sites and adjust visit intervals to minimize how many patients are at each location.

RegeneRx Biopharmaceuticals, in association with its Korean partner GtreeBNT, announced a status update in response to the COVID-19 pandemic on a phase 3 clinical trial of RGN-295 for the treatment of dry eye disease, according to a press release.

The double-masked, placebo-controlled, randomized phase 3 ARISE-3 clinical trial is expected to complete enrollment of 700 patients in the United States as planned and is nearing the interim enrollment target of 500 patients. In addition, sequential initiation will continue, with an emphasis on areas where the coronavirus is less prevalent, the release said.

Steps are being taken to manage the distance between patients at enrollment sites and adjust visit intervals to minimize how many patients are at each location.